Protective antibody responses to influenza A/H1N1/09 vaccination in children with celiac disease

J Pediatr Gastroenterol Nutr. 2012 Jun;54(6):817-9. doi: 10.1097/MPG.0b013e318248e7be.

Abstract

Patients with celiac disease have an increased risk for severe influenza infection and they show less of a response to certain vaccine types. During the influenza A/H1N1/09 pandemic, we prospectively investigated pandemic vaccine responses in 14 pediatric patients with celiac disease and age-/sex-matched controls. All of the children with celiac disease reached protective antibody titers (≥40) and showed a geometric mean titer comparable with the control group (530 vs 573).

Trial registration: ClinicalTrials.gov NCT01022905.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antibody Formation*
  • Case-Control Studies
  • Celiac Disease / complications
  • Celiac Disease / immunology*
  • Child
  • Child, Preschool
  • Disease Susceptibility
  • Female
  • Humans
  • Influenza A Virus, H1N1 Subtype*
  • Influenza Vaccines / immunology*
  • Influenza, Human / epidemiology
  • Influenza, Human / immunology
  • Influenza, Human / prevention & control*
  • Influenza, Human / virology
  • Male
  • Pandemics
  • Prospective Studies
  • Risk Factors
  • Vaccination*
  • Young Adult

Substances

  • Influenza Vaccines

Associated data

  • ClinicalTrials.gov/NCT01022905